Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

David F. McDermott, MD
Published: Wednesday, Nov 29, 2017



David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

The CheckMate-214 study evaluated the combination of PD-1 blockade with nivolumab and CTLA4 blockade with ipilimumab.

This combination was particularly impactful in patients who were intermediate- and poor-risk, as they demonstrated a longer progression-free survival, a significantly longer overall survival (OS), and a higher complete response rate, McDermott explains.
 


David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

The CheckMate-214 study evaluated the combination of PD-1 blockade with nivolumab and CTLA4 blockade with ipilimumab.

This combination was particularly impactful in patients who were intermediate- and poor-risk, as they demonstrated a longer progression-free survival, a significantly longer overall survival (OS), and a higher complete response rate, McDermott explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x